2250 Phase II trial of neoadjuvant gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy in resectable pancreatic adenocarcinoma. A GEMCAD 10–03 trial. (September 2015) - Laquente, B.; Conill, C.; Fabregat, J.; Cambray, M.; Ayuso, J.R.; Valls, C.; Bombí, J.A.; Serrano, T.; Ferrández, A.; Povés, I.; Sabater, L.; Montagut, C.; et al.